title: Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis.
abstract: BACKGROUND
  Patients with primary sclerosing cholangitis (PSC) and colonic inflammatory bowel disease (IBD) demonstrate increased risk of colorectal cancer. Prior studies have yielded conflicting information on the relationship between ursodiol (UDCA) and the risk of colorectal cancer or dysplasia in this group.
  
  
  OBJECTIVE
  To examine the impact of UDCA on risk of colorectal cancer or dysplasia in adult PSC and IBD patients.
  
  
  METHODS
  A systematic review and meta-analysis of case-control and cohort studies was performed. Subgroup analysis compared the effects of "low-to-medium" (<25 mg/kg/day) versus "high" dose (≥ 25 mg/kg/day) UDCA exposures.
  
  
  RESULTS
  Inclusion and exclusion criteria, as well as all variables, were determined a priori. Seven papers, with 707 participants and greater than 5,751 person-years of follow-up time, met the criteria for final analysis. The overall pooled relative risk using a random effects model was not statistically significant (RR = 0.87, 95 % CI 0.51-1.49, p = 0.62). Subgroup analysis by UDCA dose category in a random effects model was not statistically significant (RR = 0.64, 95 % CI 0.38-1.07, p = 0.09), but suggested a possible trend in risk reduction at low-to-medium-dose exposures that may warrant further investigation.
  
  
  CONCLUSIONS
  UDCA use was not associated with risk of colorectal cancer or dysplasia in adult PSC and IBD patients, but UDCA dose was a source of heterogeneity across studies. Subgroup analysis suggests a possible trend toward decreased colorectal cancer risk in low-to-medium-dose exposures. Additional study of UDCA treatments at low doses in PSC and IBD patients may be warranted.
authors.affiliation: Harvard School of Public Health, Boston, MA, USA, jdh817@mail.harvard.edu.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Hansen
authors.forename: Sonal
authors.initials: S
authors.lastname: Kumar
authors.forename: Wai-Kit
authors.initials: WK
authors.lastname: Lo
authors.forename: David M
authors.initials: DM
authors.lastname: Poulsen
authors.forename: Umme-Aiman
authors.initials: UA
authors.lastname: Halai
authors.forename: Kathy C
authors.initials: KC
authors.lastname: Tater
mesh_terms: D015209:Cholangitis, Sclerosing / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000209:etiology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D012307:Risk Factors; D014580:Ursodeoxycholic Acid / Q000009:adverse effects*
chemical_list: D014580:Ursodeoxycholic Acid
references.citation: Gut. 1980 Oct;21(10):870-7
references.pmid: 7439807
references.citation: Ann Intern Med. 2001 Jan 16;134(2):89-95
references.pmid: 11177311
references.citation: Hepatology. 2010 Jul;52(1):197-203
references.pmid: 20564380
references.citation: Cancer. 2001 Feb 15;91(4):854-62
references.pmid: 11241255
references.citation: Gastroenterology. 2005 Nov;129(5):1464-72
references.pmid: 16285948
references.citation: Am J Gastroenterol. 2011 Sep;106(9):1638-45
references.pmid: 21556038
references.citation: Indian J Gastroenterol. 2012 Apr;31(2):69-74
references.pmid: 22528343
references.citation: Dig Dis Sci. 2011 Dec;56(12):3624-30
references.pmid: 21656181
references.citation: JAMA. 2000 Apr 19;283(15):2008-12
references.pmid: 10789670
references.citation: Gastrointest Endosc. 2002 Jul;56(1):48-54
references.pmid: 12085034
references.citation: Gastroenterology. 2003 Apr;124(4):889-93
references.pmid: 12671884
references.citation: J Clin Gastroenterol. 1981 Sep;3(3):261-6
references.pmid: 7288119
references.citation: Clin Gastroenterol Hepatol. 2012 Mar;10(3):303-8
references.pmid: 22037429
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Cancer Res. 1994 Oct 1;54(19):5071-4
references.pmid: 7923119
references.citation: Hepatology. 2010 Feb;51(2):660-78
references.pmid: 20101749
references.citation: Can J Gastroenterol. 2008 Aug;22(8):689-98
references.pmid: 18701947
references.citation: Gastroenterol Clin North Am. 1999 Jun;28(2):459-77, x
references.pmid: 10372277
references.citation: Gastrointest Endosc. 2012 May;75(5):1045-1054.e1
references.pmid: 22405258
references.citation: N Engl J Med. 1995 Apr 6;332(14):924-33
references.pmid: 7877651
references.citation: Hepatology. 2009 Sep;50(3):808-14
references.pmid: 19585548
references.citation: Aliment Pharmacol Ther. 2012 Feb;35(4):451-7
references.pmid: 22221173
references.citation: Am J Gastroenterol. 1999 Jun;94(6):1643-9
references.pmid: 10364038
references.citation: Jpn J Cancer Res. 1998 Oct;89(10):1009-13
references.pmid: 9849578
references.citation: Aliment Pharmacol Ther. 2005 Nov 1;22(9):783-8
references.pmid: 16225486
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120